NCT03412188View on ClinicalTrials.gov

The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP.

NACompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

September 1, 2021

Study Completion Date

September 1, 2021

Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
DRUG

Eltrombopag

Patients who showed no response (platelet count ≤ 20x109/L) initially for 3 months or relapse after 6 months after at least one prior ITP therapy will receive a total daily dose of eltrombopag of (25-50mg/d)

DRUG

conventional

Patients who are currently receiving conventional lines of treatment (steroids, IVIG, azathioprine, and rituximab, Mycophenolate mofetil) will continue on the same line of treatment

Trial Locations (1)

11579

Ainshams University , Faculty of medicine , Pediatric Hematology&Oncology unit, children hospital., Cairo

All Listed Sponsors
lead

Nayera Hazaa Elsherif

OTHER

NCT03412188 - The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP. | Biotech Hunter | Biotech Hunter